PCSK9 and hyperlipidemia: In contrast, incensed levels of ANGPTL3 (OR = 2.21, 95% CI, 1.91–2.57; P = 3.88e-25), APOA5 (OR = 1.33, 95% CI, 1.27–1.39; P = 1.45e-34), APOB (OR = 9.37, 95% CI, 5.12–17.12; P = 3.58e-13), APOC3 (OR = 10.91, 95% CI, 8.69–13.70; P = 4.41e-94), BCAM (OR = 1.86, 95% CI, 1.52–2.28; P = 1.65e-09), KLK1 (OR = 1.15, 95% CI, 1.10–1.20; P = 7.15e-10), NCAN (OR = 2.34, 95% CI, 1.82–3.01; P = 4.09e-11), TAGLN (OR = 3.44, 95% CI, 2.33–5.05; P = 3.78e-10), and PCSK9 (OR = 1.81, 95% CI, 1.51–2.16; P = 6.87e-11) indicated higher risk of hyperlipidemia.